One intriguing extension from our analysis is the potential to repurpose or harness novel Wnt inhibitors or chromatin modifying drugs to ameliorate the effects of ASXL1 variants in a range of diseases, including BOS and subtypes of AML. The gene discussed is ASXL1; the disease is acute myeloid leukemia.